[All-trans retinoic acid (Tretinoin)].
Differentiation therapy with all-trans retinoic acid (ATRA, tretinoin) alone or in combination with chemotherapy induces around 90% complete remission in acute promyelocytic leukemia (APL). By giving non-cross resistant chemotherapy as postremission therapy, more than 50% of APL, especially more than 70% of APL patients of age less than 30, became curable. Since this active form of Vitamin A causes less toxicity and fewer complications compared with other cytotoxic drugs, the medical costs required are less. Therefore, ATRA therapy should be incorporated as a first-line therapy for APL.
Ohno
R
R
Dept. of Medicine III, Hamamatsu University School of Medicine.
D002454:Cell Differentiation / Q000187:drug effects; D016527:Drug Costs; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D012074:Remission Induction; D014212:Tretinoin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use
D014212:Tretinoin